EUVIMEDEUVIMED entdecken
Open Access

METTL5 reprograms glycolytic metabolism and promotes non‑small cell lung cancer progression by modifying PGAM1

Yuchen Shan, Xiaoyu Duan, Kai Yuan, Ming Lou, Qiyong Wu, Zhaojia Gao

Oncology Letters · 20.04.2026 · 31 (6) · 1-15

DOI: 10.3892/ol.2026.15609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 20.04.2026. Verfasst von Yuchen Shan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Changzhou No. 2 People's Hospital (The Third Affiliated Hospital of Nanjing Medical University), Changzhou, Jiangsu 2…. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-methyladenosine (m6A) RNA methylation is implicated in cancer metabolism; however, to the best of our knowledge, the role of methyltransferase 5 (METTL5) in non-small cell lung cancer (NSCLC) progression remains unclear. Reprogrammed glycolytic metabolism (Warburg effect) supports tumor growth and immune evasion; however, the regulatory mechanisms of this process require further investigation. We hypothesized that METTL5 drives NSCLC progression by regulating glycolytic metabolism through m6A modification of phosphoglycerate mutase 1 (PGAM1) mRNA. The present study aimed to elucidate the molecular mechanisms, functional impacts and clinical relevance of the METTL5/PGAM1 axis. Integrated analyses of NSCLC cohorts from The Cancer Genome Atlas database were performed, and in vitro models (A549 and PC9 cell lines) and molecular techniques, including methylation inhibition, RNA stability assays and metabolic flux measurements (Seahorse XFe96 analyzer), were used. Key interactions were validated through western blotting, reverse transcription-quantitative PCR and correlation analyses. METTL5 was significantly upregulated in NSCLC tissues and in A549, PC9 and H520 cell lines, and high METTL5 expression was associated with poor patient survival (P

Schlagwörter

Stichwörter der Autor:innen

N6-methyladenosine RNA methylationWarburg effectglucose transporter type 1methyltransferase 5non-small cell lung cancerphosphoglycerate mutase 1

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Changzhou No. 2 People's Hospital (The Third Affiliated Hospital of Nanjing Medical University), Changzhou, Jiangsu 213003, P.R. China.
  • Laboratory of Heart and Lung Disease, Changzhou No. 2 People's Hospital (The Third Affiliated Hospital of Nanjing Medical University), Changzhou, Jiangsu 213003, P.R. China.

Zitieren

APA

Shan, Y., Duan, X., Yuan, K., Lou, M., Wu, Q., & Gao, Z. (2026). METTL5 reprograms glycolytic metabolism and promotes non‑small cell lung cancer progression by modifying PGAM1. Oncology Letters, 31(6), 1-15. https://doi.org/10.3892/ol.2026.15609

Vancouver

Shan Y, Duan X, Yuan K, Lou M, Wu Q, Gao Z. METTL5 reprograms glycolytic metabolism and promotes non‑small cell lung cancer progression by modifying PGAM1. Oncology Letters. 2026;31(6):1-15. doi:10.3892/ol.2026.15609

BibTeX
@article{Shan2026,
  author = {Shan, Yuchen and Duan, Xiaoyu and Yuan, Kai and Lou, Ming and Wu, Qiyong and Gao, Zhaojia},
  title = {METTL5 reprograms glycolytic metabolism and promotes non‑small cell lung cancer progression by modifying PGAM1},
  journal = {Oncology Letters},
  year = {2026},
  volume = {31},
  number = {6},
  pages = {1--15},
  doi = {10.3892/ol.2026.15609}
}
Kostenlos starten →